Sissel Rodahl
Corporate Officer/Principal en GENSIGHT BIOLOGICS S.A. .
Perfil
Sissel Rodahl is currently the Senior Vice President-Commercial Operations at Gensight Biologics SA since 2022.
Prior to this, she worked as Vice President at Novartis Gene Therapies, Inc. from 2018 to 2022.
She completed her graduate degree from the University of Oslo and her undergraduate degree from Engineering College.
Cargos activos de Sissel Rodahl
| Empresas | Cargo | Inicio |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Corporate Officer/Principal | 31/01/2022 |
Antiguos cargos conocidos de Sissel Rodahl.
| Empresas | Cargo | Fin |
|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01/02/2022 |
Formación de Sissel Rodahl.
| University of Oslo | Graduate Degree |
| Engineering College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Bolsa de valores
- Insiders
- Sissel Rodahl
